{"id":178231,"date":"2023-12-13T11:40:52","date_gmt":"2023-12-13T17:40:52","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/12\/mitorx-raises-5-million-to-advance-mitochondrial-dysfunction-therapeutics"},"modified":"2023-12-13T11:40:52","modified_gmt":"2023-12-13T17:40:52","slug":"mitorx-raises-5-million-to-advance-mitochondrial-dysfunction-therapeutics","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/12\/mitorx-raises-5-million-to-advance-mitochondrial-dysfunction-therapeutics","title":{"rendered":"MitoRx raises $5 million to advance mitochondrial dysfunction therapeutics"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/mitorx-raises-5-million-to-advance-mitochondrial-dysfunction-therapeutics2.jpg\"><\/a><\/p>\n<p>Headquartered in Oxford, UK, MitoRx is working on orally delivered mitochondrial protective therapeutics targeting <a href=\"https:\/\/longevity.technology\/tag\/mitochondrial-dysfuntion\/\" target=\"_blank\" rel=\"noreferrer noopener\">mitochondrial dysfunction<\/a> linked to the progression of conditions such as Duchenne muscular dystrophy and Huntington\u2019s disease, along with other neurodegenerative diseases. The company says the new funding will be allocated towards its preclinical work in Huntington\u2019s disease, activating its first neurodegenerative disease program, and exploring research collaborations and partnerships.<\/p>\n<p>MitoRx anticipates delivering preclinical results in Duchenne muscular dystrophy, Huntington\u2019s disease, and COPD next year.<\/p>\n<p>\u201cInterim results in our Duchenne program demonstrate that our muscle-penetrative lead asset preserves strength in oxidative muscle, and confirms mitochondrial modulation,\u201d said Dr Christine Charman, Chief Development Officer at MitoRx. \u201cThese results will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in Orlando during March 2024.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Headquartered in Oxford, UK, MitoRx is working on orally delivered mitochondrial protective therapeutics targeting mitochondrial dysfunction linked to the progression of conditions such as Duchenne muscular dystrophy and Huntington\u2019s disease, along with other neurodegenerative diseases. The company says the new funding will be allocated towards its preclinical work in Huntington\u2019s disease, activating its first neurodegenerative [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-178231","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/178231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=178231"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/178231\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=178231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=178231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=178231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}